These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 682101)
1. [Bioavailability of drug products and bioequivalence requirements (author's transl)]. Jaminet F J Pharm Belg; 1978; 33(3):141-56. PubMed ID: 682101 [No Abstract] [Full Text] [Related]
2. The potential clinical significance of differences in bioavailability. Hosp Formul; 1976 Sep; 11(9):484, 487-8. PubMed ID: 10316482 [No Abstract] [Full Text] [Related]
3. [Methodological approach to the measure of the bioavailability of drugs in man (author's transl)]. Lesne M J Pharm Belg; 1976; 31(1):5-24. PubMed ID: 768445 [No Abstract] [Full Text] [Related]
4. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)]. Schnieders B Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195 [TBL] [Abstract][Full Text] [Related]
5. Importance of biopharmaceutics and pharmacokinetics in clinical medicine. Cabana BE Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194 [TBL] [Abstract][Full Text] [Related]
9. An overview of the analysis and interpretation of bioavailability studies in man. Wagner JG Arzneimittelforschung; 1976; 26(1A):105-8. PubMed ID: 947190 [TBL] [Abstract][Full Text] [Related]
10. [The role of biopharmaceutical parameters in drug development (author's transl)]. Thoma K Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191 [TBL] [Abstract][Full Text] [Related]
11. [Biopharmaceutic and pharmacokinetic parameters in assessing pharmacopoeial drug quality standards (author's transl)]. Zathurecký L Cas Lek Cesk; 1977 Apr; 116(16):481-5. PubMed ID: 872171 [No Abstract] [Full Text] [Related]
12. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends. Srinivas NR Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891 [TBL] [Abstract][Full Text] [Related]
13. Society testifies on bioavailability, bioequivalence. Hayes AH Pa Med; 1975 Sep; 78(9):59-60. PubMed ID: 1178207 [No Abstract] [Full Text] [Related]
14. Bioavailability of drugs (second of two parts). Koch-Weser J N Engl J Med; 1974 Sep; 291(10):503-6. PubMed ID: 4604153 [No Abstract] [Full Text] [Related]
15. [Bioavailability and biopharmaceutics]. Colombo BM; Colombo MM; De Fusco R Boll Chim Farm; 1976 Mar; 115(3):231-41. PubMed ID: 1275980 [No Abstract] [Full Text] [Related]
16. [Absorption and biological availability of drugs]. Uribe M Rev Gastroenterol Mex; 1977; 42(1):2-8. PubMed ID: 616972 [TBL] [Abstract][Full Text] [Related]
17. A history of biopharmaceutics in the Food and Drug Administration 1968-1993. Skelly JP AAPS J; 2010 Mar; 12(1):44-50. PubMed ID: 19936940 [TBL] [Abstract][Full Text] [Related]
18. [Bioequivalence of solid drug preparation]. Ejima A Eisei Shikenjo Hokoku; 1982; (100):1-20. PubMed ID: 6897833 [No Abstract] [Full Text] [Related]
19. A time to speak out on bioequivalence and therapeutic equivalence. Dettelbach HR J Clin Pharmacol; 1986; 26(5):307-8. PubMed ID: 2871052 [No Abstract] [Full Text] [Related]
20. Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence. García-Arieta A Eur J Pharm Sci; 2014 Dec; 65():89-97. PubMed ID: 25236823 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]